Eighty per cent of mice infected with a mouse-adapted strain ofinfluenza virus died within 3 to 8 days after infection. Rimantadine given at maximum protective doses reduced mortality to 10%. This protection is dose related and can be demonstrated with doses from 4.5 to 24 mg per kg per day. 
Eighty per cent of mice infected with a mouse-adapted strain ofinfluenza virus died within 3 to 8 days after infection. Rimantadine given at maximum protective doses reduced mortality to 10%. This protection is dose related and can be demonstrated with doses from 4.5 to 24 mg per kg per day. Significant survival rates are shown by delaying treatment as long as 48 hr after infection. Lungs of treated mice have significantly less virus than those of controls at 24, 48, and 72 hr after infection. Antibody production as measured by hemagglutination inhibition is not different in treated and controlled mice. These results indicate that rimantadine is an effective prophylactic and therapeutic agent and that its activity is associated with decreased viral titers.
Amantadine and rimantadine have prophylactic activity against infections by many strains of influenza A virus (1, 5) . Comparative studies in mice suggest that rimantadine was more effective than amantadine (11) . Human experiments during spontaneous epidemics (10) or with induced disease (2, 6, 12) have also demonstrated that rimantadine decreases the severity and duration of the disease. Dose-response studies with amantadine by McGahen (7) demonstrated that mice had an increase in survival rate and survival time when compared with controls.
The present studies were done in an attempt to quantitate survival rate and infectious particles in mice given increasing doses of rimantadine. Rimantadine was chosen because of its known effect (11) 
RESULTS
Eighty per cent of control mice died between 3 and 8 days after infection. Thirty-six hours after infection the mice appeared ill. The fur was ruffled and the mice were huddled in a corner. Water and food consumption decreased ( Fig. 1 and 2) and weight reduction was easily quantitated (Fig. 3) . Infected nontreated mice lost weight progressively until death. Infected mice treated with 24 mg of rimantadine per kg per day had an initial decrease in weight followed by a weight increase at a rate parallel to that of the controls. By the end of the experiment, they had not reached the same weight as the noninfected animals. Mice given rimantadine and not infected continued to gain weight, drink, and eat as the normals.
Mice treated with rimantadine had increased survival rates (Fig. 4 Table 2 . No significant differences were found between the control and treated groups.
DISCUSSION
Evaluation of antiinfluenza agents needs to be tested eventually in man. This evaluation is difficult because it is partially based on subjective symptomatology, subjective evaluation of physical findings, and antibody production. There are now several (2, 6, 10, 12) reports concerning the effect of rimantadine and amantadine in the prophylaxis and therapy of induced or spontaneous influenza in man. More objective data can be obtained from animals. McGahen showed that the first clinical evidence of infection in mice is decreased consumption of water (8) .
In the present study, we have shown that there is also a decreased consumption of food. As a RABINOVICH consequence mice lose weight. Measuring the weight of mice appears to be a simple and objective means to follow early infection.
In our model of mouse infection, 30 LD50 produces an 80% mortality in 7 to 9 days. Rimanta-20 onn4__- 
